Scarica l'app Stockscreener
4.22
0.94%
-0.04
Precedente Chiudi:
$4.26
Aprire:
$4.29
Volume 24 ore:
275.58K
Relative Volume:
0.66
Capitalizzazione di mercato:
$230.52M
Reddito:
$163.78M
Utile/perdita netta:
$25.88M
Rapporto P/E:
6.4923
EPS:
0.65
Flusso di cassa netto:
$-28.66M
1 W Prestazione:
-0.24%
1M Prestazione:
-19.16%
6M Prestazione:
-38.57%
1 anno Prestazione:
-44.76%
Intervallo 1D:
$4.205
$4.3537
Intervallo di 1 settimana:
$4.205
$4.53
Portata 52W:
$4.0013
$10.66
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Nome
Voyager Therapeutics Inc
Settore
Industria
Telefono
857-259-5340
Indirizzo
75 HAYDEN AVENUE, LEXINGTON, MA
Confronta VYGR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
4.22 | 230.52M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-02 | Iniziato | Citigroup | Buy |
| 2024-11-29 | Ripresa | Wedbush | Outperform |
| 2024-10-16 | Iniziato | Leerink Partners | Outperform |
| 2024-03-26 | Iniziato | Guggenheim | Buy |
| 2024-03-19 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-07 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | Iniziato | Truist | Buy |
| 2023-03-10 | Iniziato | Oppenheimer | Outperform |
| 2021-10-07 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | Downgrade | BTIG Research | Buy → Neutral |
| 2021-02-03 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-11-10 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | Iniziato | The Benchmark Company | Buy |
| 2020-02-06 | Iniziato | Oppenheimer | Outperform |
| 2018-11-15 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-09-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-02-02 | Iniziato | Morgan Stanley | Overweight |
| 2017-11-28 | Ripresa | Piper Jaffray | Overweight |
| 2017-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2017-10-27 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-23 | Reiterato | Stifel | Buy |
| 2017-10-12 | Iniziato | Raymond James | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-28 | Ripresa | Stifel | Buy |
Mostra tutto
Voyager Therapeutics Inc Borsa (VYGR) Ultime notizie
VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Morningstar
Levi & Korsinsky Reminds Voyager Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsVYGR - ACCESS Newswire
Lost Money on Voyager Therapeutics, Inc. (VYGR)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Wednesday - MarketBeat
Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of Investors - GlobeNewswire
Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of Investors - GlobeNewswire Inc.
Voyager Therapeutics stock hits 52-week low at $4.12 By Investing.com - Investing.com Nigeria
Voyager Therapeutics reassesses SOD1-ALS gene therapy program - ALS News Today
Wedbush Has Bearish Estimate for VYGR FY2025 Earnings - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc.VYGR - PR Newswire
Research Analysts Set Expectations for VYGR FY2029 Earnings - MarketBeat
Wedbush Predicts Lower Earnings for Voyager Therapeutics - Armenian Reporter
Voyager Therapeutics CEO Alfred Sandrock sells $74,065 in stock - MSN
Voyager Therapeutics (NASDAQ:VYGR) Receives "Outperform" Rating from Wedbush - MarketBeat
Equities Analysts Issue Forecasts for VYGR FY2025 Earnings - Defense World
Voyager Therapeutics COO Robin Swartz sells $30,927 in stock - MSN
Brokers Issue Forecasts for VYGR FY2029 Earnings - Defense World
A company insider recently sold 5,413 shares of Voyager Therapeutics Inc [VYGR]. Should You Sale? - Knox Daily
Voyager Therapeutics COO Robin Swartz sells $30,927 in stock By Investing.com - Investing.com Australia
Voyager Therapeutics' chief legal officer sells $19,393 in stock - MSN
Voyager Therapeutics CEO Alfred Sandrock sells $74,065 in stock By Investing.com - Investing.com Australia
Voyager Therapeutics’ chief legal officer sells $19,393 in stock By Investing.com - Investing.com Nigeria
Voyager Therapeutics stock hits 52-week low at $4.12 - MSN
Voyager Therapeutics' chief scientific officer sells shares worth $24,087 - MSN
Voyager Therapeutics’ chief scientific officer sells shares worth $24,087 By Investing.com - Investing.com Nigeria
Voyager Therapeutics' chief scientific officer sells shares worth $24,087 By Investing.com - Investing.com South Africa
Voyager Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
Voyager Therapeutics Executives Sell Shares - TradingView
Voyager Therapeutics, Inc. (VYGR): A Cheap Biotech Stock to Invest In Now - Insider Monkey
Insiders Sold Voyager Therapeutics Prematurely At US$7.47 With Stock Trading Higher - Simply Wall St
Voyager updates on SOD1 ALS gene therapy program - The Pharma Letter
Voyager Therapeutics (NASDAQ:VYGR) Given “Outperform” Rating at Wedbush - Defense World
SG Americas Securities LLC Increases Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
10 Cheap Biotech Stocks to Invest in Now - Insider Monkey
Voyager Therapeutics shifts focus for ALS therapy - MSN
Voyager Therapeutics stock tumbles after IND application delayed - MSN
Voyager Therapeutics stock tumbles after IND application delayed By Investing.com - Investing.com Canada
Voyager Therapeutics shifts focus for ALS therapy By Investing.com - Investing.com Australia
Wedbush Adjusts Price Target on Voyager Therapeutics to $9 From $11, Maintains Outperform Rating - Marketscreener.com
Voyager Provides Update on SOD1 ALS Gene Therapy Program - GlobeNewswire
Journey of Voyager's ALS gene therapy to clinic hindered by need to find alternative payload - Fierce Biotech
Voyager Therapeutics Shares Fall After Dropping Plan for VY9323 IND Filing in Mid-2025 - Marketscreener.com
Voyager Therapeutics Inc Azioni (VYGR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):